AstraZeneca and Oracle partner to advance AI in clinical trials

AstraZeneca PLC and Oracle Corp on Tuesday announced a global collaboration to use artificial intelligence to improve clinical trials, patient diagnosis and treatment.

The Cambridge, England-based pharmaceutical company said the partnership will combine its scientific and clinical development expertise with Austin, Texas-based Oracle's real-world data, cloud infrastructure and AI capabilities.

The collaboration will focus on improving clinical trial recruitment, enabling earlier diagnosis, strengthening drug-safety monitoring and using real-world evidence to support patient care.

Projects will cover AstraZeneca's core therapeutic areas, including oncology, cardiovascular, renal and metabolic diseases, respiratory and immunology, and rare diseases.

The partnership will span the US, Middle East and Europe, with the first programme focusing on hypertension care and clinical research in Abu Dhabi, alongside healthcare company M42.

The initial project aims to help clinicians identify patients with uncontrolled hypertension, improve adherence to treatment guidelines and support recruitment for clinical trials.

"This unique collaboration brings leaders in healthcare and AI together at a global scale to accelerate the journey from the discovery of medicine to patient care," said AstraZeneca Chief Executive Pascal Soriot.

"Combining AstraZeneca's world class science with Oracle's deep data and technology expertise, we can help clinicians identify patients sooner, optimise clinical trials, and generate evidence continuously across the lifecycle of a medicine."

The companies said they have signed a non-binding term sheet, with no financial details disclosed.

AstraZeneca shares were 0.9% higher at 12,506.00 pence in London on Tuesday morning. Oracle shares were 1.5% lower at USD127.70 in New York during premarket trading.

Copyright 2026 Alliance News Ltd. All Rights Reserved.